###begin article-title 0
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
###xml 7 14 7 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP-1</italic>
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP-3</italic>
IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)
###end article-title 0
###begin p 1
Performed the experiments: SC. Analyzed the data: LD AP. Wrote the paper: AP. Other: Critical review: MT CB FC LL SC EC JB MD FC-C CH LD RH BH SH LK RK DH JM EL JL PK MP MCP PP CM HF RZ MY RT DT RCT AT DS ER IC. Expert advice: HF DH CH DC FC IC. Writing team: HF FC LL MT IC.
###end p 1
###begin p 2
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 797 803 797 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 808 814 808 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1021 1025 1021 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1040 1046 1040 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 1051 1057 1051 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1068 1072 1068 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1164 1170 1164 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1431 1435 1431 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1437 1443 1437 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 1448 1454 1448 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1746 1750 1746 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1755 1761 1755 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 610 615 <span type="species:ncbi:9606">women</span>
###xml 1905 1910 <span type="species:ncbi:9606">women</span>
IGF-1 has been shown to promote proliferation of normal epithelial breast cells, and the IGF pathway has also been linked to mammary carcinogenesis in animal models. We comprehensively examined the association between common genetic variation in the IGF1, IGFBP1, and IGFBP3 genes in relation to circulating IGF-I and IGFBP-3 levels and breast cancer risk within the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). This analysis included 6,912 breast cancer cases and 8,891 matched controls (n = 6,410 for circulating IGF-I and 6,275 for circulating IGFBP-3 analyses) comprised primarily of Caucasian women drawn from six large cohorts. Linkage disequilibrium and haplotype patterns were characterized in the regions surrounding IGF1 and the genes coding for two of its binding proteins, IGFBP1 and IGFBP3. In total, thirty haplotype-tagging single nucleotide polymorphisms (htSNP) were selected to provide high coverage of common haplotypes; the haplotype structure was defined across four haplotype blocks for IGF1 and three for IGFBP1 and IGFBP3. Specific IGF1 SNPs individually accounted for up to 5% change in circulating IGF-I levels and individual IGFBP3 SNPs were associated up to 12% change in circulating IGFBP-3 levels, but no associations were observed between these polymorphisms and breast cancer risk. Logistic regression analyses found no associations between breast cancer and any htSNPs or haplotypes in IGF1, IGFBP1, or IGFBP3. No effect modification was observed in analyses stratified by menopausal status, family history of breast cancer, body mass index, or postmenopausal hormone therapy, or for analyses stratified by stage at diagnosis or hormone receptor status. In summary, the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 112 115 112 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Sachdev1">[1]</xref>
###xml 117 120 117 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wood1">[2]</xref>
###xml 466 469 466 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Baxter1">[3]</xref>
###xml 551 554 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Sachdev1">[1]</xref>
###xml 556 559 556 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wood1">[2]</xref>
###xml 561 564 561 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Burger1">[4]</xref>
###xml 641 644 641 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Hadsell1">[5]</xref>
The insulin-like growth factor-I (IGF-I) signaling pathway stimulates cell proliferation and inhibits apoptosis [1], [2]. The bioavailability of IGF-I in circulation and tissues is determined by the amount of free ligand that circulates unattached to binding protein. There are six IGF binding proteins. Approximately 75-90% of IGF-I binds to IGFBP-3, limiting its bioavailability. IGFBP-1 also modulates IGF-I bioavailability, and is inversely regulated by insulin [3]. IGF-I has been shown to promote proliferation of normal epithelial breast cells [1], [2], [4]. The IGF pathway has been linked to mammary carcinogenesis in animal models [5], and consequently, it has been extensively examined in relation to breast cancer pathogenesis.
###end p 4
###begin p 5
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Allen1">[7]</xref>
###xml 237 240 237 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 296 308 296 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP1</italic>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 640 643 640 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 685 688 685 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF</italic>
###xml 759 762 759 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 764 767 764 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Canzian1">[8]</xref>
###xml 769 772 769 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Johansson1">[10]</xref>
###xml 780 784 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Setiawan1">[11]</xref>
###xml 786 790 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Verheus1">[12]</xref>
###xml 941 953 941 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP1</italic>
###xml 959 965 959 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1014 1017 1014 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Canzian1">[8]</xref>
###xml 1019 1022 1019 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 1024 1028 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Setiawan1">[11]</xref>
Previous epidemiologic studies have suggested that high circulating levels of IGF-I and low levels of IGFBP-3 are associated with increased risk of premenopausal breast cancer [6], [7]. Numerous recent epidemiologic studies (reviewed in [6]) have begun to examine variation in the genes encoding IGF1, IGFBP1, and IGFBP3 in relation to breast cancer risk. The most extensively examined polymorphisms in IGF1 has been the 5' simple tandem repeat that lies 1-kb upstream from the IGF1 gene transcription start site (the most common allele in Caucasians is the 19 CA repeat) and an A/C polymorphism 5' to IGFBP3 at nucleotide -202 (rs2854744) [6]. Some studies report that these or other IGF polymorphisms modestly affect circulating levels of IGF-I and IGFBP-3 [6], [8], [9], [10], [11], [12], but there is limited support for a direct effect on breast cancer risk. Most recently, comprehensive analyses of common genetic variation across the IGF1, IGFBP1, and IGFBP3 genes were conducted in two prospective cohorts [8], [9], [11], but no association with breast cancer risk was observed.
###end p 5
###begin p 6
###xml 71 83 71 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP1</italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Hunter1">[13]</xref>
To comprehensively examine the role of common genetic variation in the IGF1, IGFBP1, and IGFBP3 genes in relation to circulating IGF-I and IGFBP-3 levels and breast cancer risk, we conducted a haplotype-based analysis in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) [13]. The large size of this study (cases = 6,912/controls = 8,891) enabled us to detect modest genetic effects, explore gene-environment interactions, and examine potentially important subclasses of tumors, such as those defined by stage or hormone receptor status.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
Study Population
###end title 8
###begin p 9
###xml 48 52 48 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Hunter1">[13]</xref>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Calle1">[14]</xref>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Riboli1">[15]</xref>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Colditz1">[16]</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Rexrode1">[17]</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Kolonel1">[18]</xref>
###xml 742 746 742 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Hayes1">[19]</xref>
###xml 562 567 <span type="species:ncbi:9606">Women</span>
###xml 781 786 <span type="species:ncbi:9606">women</span>
The BPC3 has been described in detail elsewhere [13]. Briefly, the consortium includes large well-established cohorts assembled in the United States or Europe that have DNA for genotyping and extensive questionnaire data from cohort members. This analysis includes 6,912 cases of invasive breast cancer and 8,891 matched controls from six cohorts: the American Cancer Society Cancer Prevention Study-II (CPS-II; [14]), the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort [15], the Harvard Nurses' Health Study (NHS; [16]), the Harvard Women's Health Study (WHS; [17]), the Hawaii-Los Angeles Multiethnic Cohort Study (MEC; [18]), and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial cohort (PLCO; [19]). With the exception of MEC, most women in these studies are Caucasian. Written informed consent was obtained from all subjects, and each cohort has been approved by the following institutional review boards: Emory University (CPS-II), International Agency for Research on Cancer (IARC) and each EPIC recruitment center (EPIC), Harvard University (NHS and WHS), University of Hawaii and University of Southern California (MEC), and the U.S. National Cancer Institute and the 10 study screening centers (PLCO).
###end p 9
###begin p 10
Cases were initially identified in each cohort by self-report and subsequently verified from medical records or tumor registries and/or linkage with population-based cancer registries. In all cohorts, questionnaire data were collected prospectively before the cancer diagnosis. Controls were matched to cases by age, ethnicity (except in PLCO), and in some cohorts additional matching criteria were utilized (e.g. date of blood draw).
###end p 10
###begin title 11
SNP Selection and Genotyping
###end title 11
###begin p 12
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 135 138 135 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng2">[20]</xref>
###xml 173 185 173 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP1</italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 660 664 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Gabriel1">[21]</xref>
###xml 788 789 764 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 789 790 765 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The details of IGF1, IGFBP1 and IGFBP3 characterization and selection of haplotype-tagging SNPs (htSNPs) have been described elsewhere [9], [20]. Briefly, coding regions of IGF1, IGFBP1, and IGFBP3 were sequenced in a panel of 95 advanced breast cancer cases from the MEC (19 from each of the five ethnic groups; African American, Latina, Japanese, Native Hawaiian, and Caucasian). SNPs were also selected from public databases to capture the genetic diversity of regions from approximately20 kb upstream to approximately10 kb downstream of each gene. Haplotype blocks (regions of strong linkage disequilibrium) were defined using the method of Gabriel et al. [21]. Haplotype tagging SNPs (htSNPs) were selected to predict the common haplotypes among Caucasians that meet a criterion of rh2>0.80.
###end p 12
###begin p 13
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(18)</italic>
###xml 312 313 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 616 620 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Stram1">[22]</xref>
###xml 673 674 671 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 674 675 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 715 721 713 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 726 732 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 848 852 846 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(18)</italic>
###xml 1229 1230 1227 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 1230 1231 1228 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1271 1277 1269 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1372 1378 1370 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1458 1464 1456 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 1469 1475 1467 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 2099 2103 2097 2101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 2105 2111 2103 2109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 2117 2123 2115 2121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 2375 2379 2373 2377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Packer1">[23]</xref>
For genetic characterization of IGF1, 154 SNPs were genotyped a multiethnic panel of 349 individuals with no history of cancer (18). Of the 154 SNPs genotyped, 53 were identified as monomorphic and 37 had poor genotyping results (i.e., genotyped </=75% of samples or out of Hardy-Weinberg equilibrium [one-sided P<.01] in more than one ethnic group)-these 90 SNPs were eliminated from further analysis. The remaining 64 SNPs were used for genetic characterization and had an average density of one SNP for every 2.4 kb over a 156-kb region. Fourteen htSNPs were selected using the expectation-maximization algorithm [22] to predict the common haplotypes among Caucasians (rh2>0.85). For genetic characterization of IGFBP1 and IGFBP3 (which are located contiguously in a 35kb region of chromosome 7), 56 SNPs were genotyped in the multiethnic panel (18). Of the 56 SNPs genotyped, 17 were identified as monomorphic and 3 had poor genotyping results (as discussed above)-these 20 SNPs were eliminated from analysis. The remaining 36 SNPs were used for genetic characterization, having an average density of one SNP for every 2 kb over a 71-kb region. Twelve htSNPs were selected to predict the common haplotypes among Caucasians (rh2>0.99). Additionally, two genic SNPs in IGFBP3 that were not part of a haplotype block were examined (rs6670, rs2453839), and two additional IGFBP3 SNPs (rs2132570, and rs2960436) were included. Thus, a total of 16 SNPs across IGFBP1 and IGFBP3 were evaluated. Genotyping of breast cancer cases and controls was performed in four laboratories (University of Southern California, Los Angeles, CA USA, Harvard School of Public Health, Boston, MA USA, International Agency for Research on Cancer, Lyon, France, National Cancer Institute Core Genotyping Facility, Gaithersburg, MD USA) using a fluorescent 5' endonuclease assay and the ABI-PRISM 7900 for sequence detection (Taqman). Initial quality control checks of the SNP assays were done at the manufacturer (ABI, Foster City, CA); an additional 500 test reactions were run by the BPC3. Assay characteristics for the IGF1, IGFBP1, and IGFBP3 htSNPs are available on a public website (). To assess interlaboratory variation, each genotyping center ran assays on a designated set of 94 samples from the Coriell Biorepository (Camden, NJ) (22). The completion and concordance rates were each >99%[23]. The internal quality of genotype data at each genotyping center was assessed by typing 5-10% blinded samples in duplicate or greater, depending on study.
###end p 13
###begin title 14
IGF-I and IGFBP-3 Measurements
###end title 14
###begin p 15
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-DeLellis1">[24]</xref>
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Rinaldi1">[25]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Schernhammer1">[26]</xref>
###xml 510 515 <span type="species:ncbi:9606">women</span>
###xml 536 541 <span type="species:ncbi:9606">women</span>
IGF-I and IGFBP-3 levels were measured by enzyme-linked immunosorbent assays among non-users of postmenopausal hormones (and non-users of oral contraceptives in EPIC). Detailed laboratory methods for these studies have been previously reported [24], [25], [26]. Blood samples analyzed in this study include all cohorts with the exception of the CPS-II and WHS cohorts, where most specimens were collected after diagnosis (CPS-II) or hormone assays were not performed (WHS). Thus, these analyses included 6,410 women for IGF-I and 6,275 women for IGFBP-3.
###end p 15
###begin title 16
Statistical Analysis
###end title 16
###begin p 17
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 480 484 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 489 494 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP</italic>
In our hormone analyses, circulating IGF-I and IGFBP-3 values were naturally log-transformed to provide approximate normal distributions. Geometric mean levels of IGF-I and IGFBP-3 for IGF1 and IGFBP3 SNPs were calculated using linear regression analysis while adjusting for age at blood draw, assay laboratory and batch for circulating IGFs, BMI, race/ethnicity, and country within EPIC cohort. Additional regression analyses were conducted simultaneously adjusted for all other IGF1 and IGFBP SNPs to determine the best fit model of circulating levels.
###end p 17
###begin p 18
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Zaykin1">[27]</xref>
In our breast cancer analysis, we examined both single SNP and haplotype effects on breast cancer risk. For single SNP analyses, we used conditional multivariate logistic regression to estimate odds ratios (ORs) for breast cancer using a linear (log-odds additive) scoring for 0, 1 or 2 copies of the minor allele of each SNP. For the haplotype analyses, we calculated haplotype frequencies and subject-specific expected haplotype counts separately for each cohort, by country within EPIC, and by ethnicity within the MEC. An expectation-substitution approach was used to assign expected haplotype counts based on unphased genotype data and to account for uncertainty in assignment [27]. The most common haplotype was used as the referent group. Rare haplotypes (those with estimated individual frequencies <5%) were combined into a single category.
###end p 18
###begin p 19
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 435 436 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
To test the global null hypothesis of no association between variation in IGF1, IGFBP1, or IGFBP3 haplotypes and risk of breast cancer (or subtypes defined by receptor status), we used a likelihood ratio test comparing a model with additive effects for each common haplotype (treating the most common haplotype as the referent) to the intercept-only model. To test for heterogeneity across cohorts and ethnic groups, we used the Wald X2 for the htSNPs and a likelihood ratio test for the haplotypes.
###end p 19
###begin p 20
###xml 1086 1098 1086 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP1</italic>
###xml 1103 1109 1103 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1217 1224 1217 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
We considered conditional models both without and with adjustment for known breast cancer risk factors. These included menopausal status (premenopausal, postmenopausal), age at menopause (<50, 50+, age unknown), BMI (<25, 25-<30, 30+, missing), parity (ever, never, missing), use of postmenopausal hormones (ever, never, missing), first-degree family history of breast cancer (yes, no, unknown), age at menarche (<13, 13-14, 15+, missing), and use of oral contraceptives (ever, never, missing). Because results remained virtually unchanged regardless of the model used, we present results from the conditional models adjusting for matching factors only. We also evaluated BMI, family history of breast cancer, and use of postmenopausal hormones for possible interaction effects using likelihood ratio testing (LRT). Models with the main effect of genotype and the covariate of interest were compared to models with the main effects of genotype and the covariate of interest, plus a multiplicative interaction term of the two variables. We also examined whether the associations between IGF1, IGFBP1, or IGFBP3 htSNPs or haplotypes and breast cancer differed by menopausal status (pre- versus post-menopausal), stage (in situ versus localized versus regional or distant metastasis) or hormone receptor (ER and PR) status.
###end p 20
###begin p 21
###xml 87 90 87 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Setiawan1">[11]</xref>
###xml 106 109 106 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Canzian1">[8]</xref>
###xml 242 254 <span type="species:ncbi:9606">participants</span>
Lastly, this analysis includes a portion of the previously published data from the MEC [9], [11] and EPIC [8] cohorts (n = 2,522 breast cancer cases). Thus, all associations were examined in sub-analyses that excluded the MEC and EPIC cohort participants.
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 42 48 42 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002578-g001">Fig. 1</xref>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 91 97 91 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002578-g002">Fig. 2</xref>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
The genomic structure of IGF1 is shown in Fig. 1 and that of IGFBP1 and IGFBP3 is shown in Fig. 2. The IGF1 locus was characterized into four haplotype blocks. IGFBP1 and IGFBP3 loci are 19kb apart and were characterized by three haplotype blocks. The genotyping success rate was >/=95% for all SNPs at each genotyping center. No deviation from Hardy-Weinberg equilibrium was observed among the controls overall (at the p<0.01 level). The frequencies of individual SNPs and common haplotypes within each LD block were consistent across all cohorts (data not shown).
###end p 23
###begin title 24
IGF1 SNPs and linkage disequilibrium.
###end title 24
###begin p 25
64 SNPs were identified covering a 56-kb region. Of these, 14 htSNPs defined the common haplotypes among Caucasians.
###end p 25
###begin title 26
IGFBP1 and IGFBP3 SNPs and linkage disequilibrium.
###end title 26
###begin p 27
36 SNPs were identified covering a 71-kb region. Of these, 12 htSNPs defined the common haplotypes among Caucasians.
###end p 27
###begin p 28
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Feigelson1">[28]</xref>
###xml 174 179 <span type="species:ncbi:9606">women</span>
Study characteristics of each cohort (except PLCO) have been published previously [28]. Briefly, case and control characteristics were comparable across all cohorts and most women were postmenopausal (n = 5,474 cases and 9,732 controls) and Caucasian. As there was no heterogeneity in results across cohorts for any main effects analyses, we only reported results from pooled analyses across all cohorts combined. Additionally, haplotype analyses did not contribute additional information beyond individual SNP results, thus we reported only results for all individual SNPs within each haplotype block.
###end p 28
###begin p 29
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 14 21 14 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002578-t001">Table 1</xref>
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 35 42 35 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002578-t002">Table 2</xref>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 579 583 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP</italic>
###xml 716 722 716 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 916 920 916 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 925 930 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP</italic>
###xml 120 125 <span type="species:ncbi:9606">women</span>
SNPs in IGF1 (Table 1) and IGFBP3 (Table 2) were associated with circulating IGF-I and IGFBP-3 levels, respectively, in women not taking postmenopausal hormones. SNPs in IGF1 block 1 were most closely associated with circulating levels; the variant alleles were significantly associated with higher circulating IGF-I levels (trend p = 0.0075 for rs7965399 and p = 0.0262 for rs35767). However, these SNPs (wild type vs. variant homozygote) individually accounted for less than a 5% change in mean IGF-I levels. Results did not differ after simultaneously adjusting for all other IGF1 and IGFBP SNPs in the regression analysis (data not shown). The strongest relationships for IGFBP-3 were observed with five SNPs in IGFBP3 block 3: rs3110697, rs2854746, rs2854744, rs2132570, rs2960436 (trend p<0.001 for all). Rs2854746 remained significantly associated with IGFBP-3 levels (p<0.0001) after adjusting for all other IGF1 and IGFBP SNPs simultaneously in the regression analysis. These SNP associations account for a change in mean circulating IGFBP-3 levels ranging from 6% (rs2132570) to 12% (rs2854746).
###end p 29
###begin title 30
Associations between IGF1 SNPs and mean circulating IGF-I and IGFBP-3 levels in the BPC3.
###end title 30
###begin title 31
Associations between IGFBP1 and IGFBP3 SNPs and mean circulating IGF-I and IGFBP-3 levels in the BPC3.
###end title 31
###begin p 32
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 141 149 141 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002578-t003">Tables 3</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002578-t004">4</xref>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 169 177 169 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1/3</italic>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 714 720 714 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 568 573 <span type="species:ncbi:9606">women</span>
###xml 621 626 <span type="species:ncbi:9606">women</span>
None of the IGF1 and IGFBP3 SNPs associated with circulating IGF-I and IGFBP-3 levels were significantly associated with breast cancer risk (Tables 3 and 4 for IGF1 and IGFBP1/3, respectively), nor were other SNPs or haplotypes consistently associated with risk. When examining these associations among invasive breast cancer only, by stage, or by hormone-receptor status, we did not observe any associations between variation in these genes and disease risk (data not shown). Results did not differ when examining associations separately for pre- and post-menopausal women or when restricting the analysis to only white women (data not shown). No consistent interactions were observed among variants in the IGF1, IGFBP1, and IGFBP3 genes with any of the following: first-degree family history of breast cancer, ever oral contraceptive use, use of postmenopausal hormones, and BMI (<25, 25-<30, 30+). We observed no interactions resulting in sub-group associations with disease risk (data not shown).
###end p 32
###begin title 33
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
Association of tagging SNPs of IGF1 and breast cancer risk in the BPC3.
###end title 33
###begin p 34
Adjusted for age, race/ethnicity, and country within EPIC cohort.
###end p 34
###begin title 35
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
Association of tagging SNPs of IGFBP1 and IGFBP3 and breast cancer risk in the BPC3.
###end title 35
###begin p 36
Adjusted for age, race/ethnicity, and country within EPIC cohort
###end p 36
###begin p 37
Across all statistical tests performed in relation to disease status, we observed fewer significant findings than those expected by chance alone (15 findings significant at p<0.05; 40 expected by chance alone). None of these findings provided clear evidence for main effect or subgroup associations for any of the SNPs or common haplotypes. Thus we believe these sporadic associations may reflect chance. Finally, we repeated all analyses excluding subjects from the MEC and EPIC cohorts, and found no meaningful differences in associations when compared to overall findings (data not shown).
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 791 794 791 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 854 859 <span type="species:ncbi:9606">women</span>
Our study is by far the largest to examine genetic variation in the IGF1, IGFBP1, and IGFBP3 genes in relation to both circulating IGF-I and IGFBP-3 levels and breast cancer risk. Several genetic variants in IGF1 and IGFBP3 predicted circulating levels of IGF-I and IGFBP-3, respectively, but no associations between these variants and breast cancer, overall or in subgroups, were seen. It is thus unlikely that these polymorphisms and their associated hormone levels substantially affect breast cancer risk. There was also no evidence of effect modification by selected breast cancer risk factors or subgroup effects, including menopausal status. While some previous epidemiologic studies have shown stronger support for a role of the IGF-I signaling pathway in premenopausal breast cancer [6], but we did not observe an association among premenopausal women alone.
###end p 39
###begin p 40
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Canzian1">[8]</xref>
###xml 219 222 219 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Setiawan1">[11]</xref>
###xml 503 515 503 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP1</italic>
###xml 520 526 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 575 578 575 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 580 584 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Schernhammer2">[29]</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Slattery1">[30]</xref>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wagner1">[31]</xref>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 654 655 654 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 707 711 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 739 742 739 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wagner1">[31]</xref>
###xml 864 867 864 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 979 983 979 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 988 990 988 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> n</sub>
###xml 1037 1041 1037 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-DeLellis1">[24]</xref>
Our findings are consistent with two previous studies that comprehensively examined the role of IGF1, IGFBP1, and IGFBP3 genetic variation in relation to circulating IGF-I and IGFBP-3 levels and breast cancer risk [8], [9], [11]. Cases and controls from these two studies (EPIC and MEC) were included in the pooled analysis. However, sensitivity analyses that excluded these studies also found an association with circulating hormone levels. Other studies have primarily examined individual variants in IGF1, IGFBP1, or IGFBP3 in relation to breast cancer with mixed results [6], [29], [30], [31]. The most extensively studied variant in IGF1 is the (CA)n repeat polymorphism that lies 1-kb upstream of the IGF1 transcriptional start site [6], [31]. Some previous studies observed an association between this polymorphism and circulating IGF-I levels (reviewed in [6]); however, most did not observe a corresponding association with breast cancer risk. While we did not genotype IGF1 (CA) n polymorphism, we used data from a prior study [24] and determined that the less common repeat length for this polymorphism is in LD with the minor alleles of htSNPs in block 1, rs7965399 and rs35767. Thus, our reported associations with htSNPs in block 1 and circulating IGF-I levels appear consistent with previous literature, that genetic variation influences circulating IGF-I levels, but not at a level substantial enough to impact breast cancer risk.
###end p 40
###begin p 41
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Canzian1">[8]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Schernhammer2">[29]</xref>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Slattery1">[30]</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wagner1">[31]</xref>
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Schernhammer2">[29]</xref>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Slattery1">[30]</xref>
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wagner1">[31]</xref>
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Fletcher1">[6]</xref>
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Canzian1">[8]</xref>
###xml 275 278 275 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Cheng1">[9]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Schernhammer2">[29]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Slattery1">[30]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Wagner1">[31]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Schernhammer1">[26]</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002578-Slattery1">[30]</xref>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
The A/C polymorphism at nucleotide -202 in IGFBP3 (rs2854744), and located in haplotype block 3, has been the most extensively examined polymorphism in the IGF binding proteins[6], [8], [9], [29], [30], [31]. Some [6], [29], [30], [31] but not all previous studies [6], [8], [9], [29], [30], [31] have reported an association with breast cancer . This polymorphism has also been associated with circulating levels of IGFBP-3 [26], [30]. Our study confirms the previously reported findings with circulating IGFBP-3 levels, but neither the polymorphism (within Block 3 of IGFBP3 gene) nor the haplotype block were associated with breast cancer risk in our data.
###end p 41
###begin p 42
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP1</italic>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 319 324 <span type="species:ncbi:9606">women</span>
Strengths of the BPC3 include its size and the comprehensive characterization of variation around the IGF1, IGFBP1, and IGFBP3 loci. The latter allows our analysis to provide powerful null evidence against a main effect association between breast cancer risk and variants in these genes that are common among Caucasian women as well as in defined subgroups of the study population.
###end p 42
###begin p 43
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 422 427 <span type="species:ncbi:9606">women</span>
In summary, results from this large collaborative study support previous evidence that specific genetic variants in IGF1 and IGFBP3 genes significantly influence circulating levels of IGF-I and IGFBP-3, respectively, but have no measurable effect on breast cancer risk. Given the large size of our study, it is unlikely that these loci contribute substantially to breast cancer risk among white, primarily postmenopausal, women, at the population level.
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
The IGF system and breast cancer.
###end article-title 45
###begin article-title 46
IGFs and IGFBPs in the normal mammary gland and in breast cancer.
###end article-title 46
###begin article-title 47
###xml 51 56 <span type="species:ncbi:9606">human</span>
Insulin-like growth factor binding proteins in the human circulation: a review.
###end article-title 47
###begin article-title 48
Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer.
###end article-title 48
###begin article-title 49
IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.
###end article-title 49
###begin article-title 50
Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review.
###end article-title 50
###begin article-title 51
A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk.
###end article-title 51
###begin article-title 52
Polymorphisms of genes coding for insulin-like growth factor I and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study.
###end article-title 52
###begin article-title 53
Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: The Multiethnic Cohort.
###end article-title 53
###begin article-title 54
Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels.
###end article-title 54
###begin article-title 55
IGF-I genetic variation and breast cancer: the Multiethnic Cohort.
###end article-title 55
###begin article-title 56
Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density.
###end article-title 56
###begin article-title 57
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes.
###end article-title 57
###begin article-title 58
The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.
###end article-title 58
###begin article-title 59
European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection.
###end article-title 59
###begin article-title 60
###xml 53 58 <span type="species:ncbi:9606">women</span>
The Nurses' Health Study: lifestyle and health among women.
###end article-title 60
###begin article-title 61
###xml 28 40 <span type="species:ncbi:9606">participants</span>
###xml 48 53 <span type="species:ncbi:9606">Women</span>
Baseline characteristics of participants in the Women's Health Study.
###end article-title 61
###begin article-title 62
A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.
###end article-title 62
###begin article-title 63
Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
###end article-title 63
###begin article-title 64
Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.
###end article-title 64
###begin article-title 65
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome.
###end article-title 65
###begin article-title 66
Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study.
###end article-title 66
###begin article-title 67
SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes.
###end article-title 67
###begin article-title 68
IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort.
###end article-title 68
###begin article-title 69
###xml 41 46 <span type="species:ncbi:9606">women</span>
IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).
###end article-title 69
###begin article-title 70
Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
###end article-title 70
###begin article-title 71
Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals.
###end article-title 71
###begin article-title 72
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohorts.
###end article-title 72
###begin article-title 73
Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk.
###end article-title 73
###begin article-title 74
###xml 75 80 <span type="species:ncbi:9606">women</span>
Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States.
###end article-title 74
###begin article-title 75
Polymorphisms in the IGF-1 and IGFBP-3 promoter and the risk of breast cancer.
###end article-title 75
###begin p 76
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 76
###begin p 77
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Grant support from National Cancer Institute cooperative agreements U01-CA98233, U01-CA98710, U01-CA98216, and U01-CA98758 and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics.
###end p 77

